J&J Delay Is Latest Setback to South Africa Vaccination Plans
(Bloomberg) -- South Africa said a delivery of 1.1 million Johnson & Johnson coronavirus vaccines has been delayed pending further safety checks, the latest blow to the country's stop-start inoculation program.
The government ordered 31 million of J&J's single-dose shots and planned to begin issuing them to people over the age of 60 starting May 17. The doses are ready to be issued by Durban-based drugmaker Aspen Pharmacare Holdings Ltd., which has a deal with J&J to complete the final stage of production, but they won't now be delivered by early this week as previously expected.
Instead, a protracted safety verification process has to be undertaken in conjunction with international regulatory agencies, Health Minister Zweli Mkhize said in a statement Sunday. The precaution was taken following a production glitch at a plant operated by Emergent BioSolutions Inc. in the U.S., where materials for J&J shots were mixed with those used in doses developed by U.K. drugmaker AstraZeneca Plc, which were made at the same facility.
“We are confident that the final outcome will be positive and that, provided there are no further disruptions, Johnson & Johnson will be in a position to release the stock from the Aspen plant” by mid-May, Mkhize said.
Read more: Tens of Millions of J&J Doses Sit on Shelves, Await FDA Nod
It's likely to take several days for the vaccines to make their way to inoculation sites once they are dispatched, meaning the May 17 target date for their roll-out may be missed. That's a scenario the government will want to avoid, given it's contending with Africa's worst coronavirus outbreak and facing criticism that it has not been proactive enough in securing vaccines.
South Africa has already given 318,670 health-care workers the J&J shot as part of a study that enabled it to bypass normal licensing procedures. That program, which aims at inoculating 500,000 people, was paused for two weeks last month amid concern that the shot may lead to blood clots, but it won't be affected by the latest holdup because those doses weren't produced at Aspen's plant.
The government's plans to issue AstraZeneca's vaccines were shelved in February after a small study showed they had little effect on mild infections caused by a variant of the virus first identified in South Africa. Besides the J&J shots, the government has also ordered about 30 million vaccines from Pfizer Inc., with the first 325,260 doses arriving on Sunday night and a total of 4.5 million expected by the end of next month.
More than 1.58 million Covid-19 cases have been detected in the country and over 54,000 of those diagnosed with the disease have died.
©2021 Bloomberg L.P.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.